Centers | ||
|
|
|
EU-OPENSCREEN | Edinburgh Drug Discovery | test |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
sfgd |
Partnerships |
Events |
Jobs |
Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all XenoTech / XenoGesis
View all |
No EVENTS for listing |
No Job Posts |
